biostudies-literatureUnknown20(12)Judd J<i>KRAS</i> is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different <i>KRAS</i> mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, <i>KRAS</i>-mutated non-small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development.Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of <i>KRAS</i> mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were aMolecular cancer therapeutics2577-2584https://www.ebi.ac.uk/biostudies/studies/S-EPMC9662933biostudies-literatureCharacterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.PMC9662933Socinski MAKim CKorn WMMamdani HNieva JJde Lima Lopes GLiu SVBorghaei HXiu JKim ESIkpeazu CNaqash ARKhan HWozniak AJJudd JAbdel Karim NBaca YNagasaka MVanderWalde AMPai SGSpira AIRaez LEfalseCharacterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.<i>KRAS</i> is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different <i>KRAS</i> mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, <i>KRAS</i>-mutated non-small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development.Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of <i>KRAS</i> mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were a2021-01-01T00:00:00Z2021 Dec2025-07-11T03:03:58.994Z2025-07-11T03:03:58.994ZS-EPMC96629333451829510.1158/1535-7163.MCT-21-0201